BOSTON, Mass. (
) -- The Biotech Stock Mailbag is back for its regular Friday installment. I hope you enjoyed the
bonus edition Wednesday
. And remember, I'm already on vacation as you read this, so no Mailbag next week, but please don't stop sending me your emails. I will get to them when I return -- relaxed, rested and hopefully a darker shade of pale (after a liberal application of SPF 50, of course).
Paul gets things kicking with a comment about my
(BCRX - Get Report)
perhaps being a bit over-valued as a swine flu drug stock already.
"Gee Adam...here is more of the 'hype' you refer to. I guess several hundred million people with swine flu, and hundreds of thousands of deaths projected by the World Health Organization is just hype, as you put it. It would be really helpful if you could contact all these organizations and world experts and let them know that you have far more knowledge in this area, and they should just relax and not fall prey to the hype."
Attached to Paul's email, titled "BCRX, swine flu and the hype," was an article about H1N1 flu, which included a quote from the University of Michigan's Arnold Monto, an advisor to the CDC and a noted flu expert, predicting that upwards of 100 million Americans will catch swine flu, leaving anywhere from 30,000 to 90,000 people dead.
I don't think I'm going out on a ledge here by assuming Paul own shares in Biocryst and believes the U.S. government, and foreign governments, too, will be buying Biocryst's injectable flu drug peramivir by the truckload in order to treat patients who might be hospitalized by the coming swine flu plague.